Drugs / budesonide/formoterol
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00421122 | Sep 2006 → Nov 2007 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-11-10 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Viatris Wins Court Decision Invalidating AstraZeneca's Symbicort® Patent viatris.com ↗ |
| 2021-03-08 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Viatris Inc. and Kindeva Drug Delivery Announce FDA Tentative Approval of the First Abbreviated New Drug Application Generic Version of Symbicort® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol viatris.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | budesonide/formoterol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00421122 ↗ |
| Known as | Symbicort | “budesonide/formoterol (Symbicort)” NCT00421122 ↗ |
| Route | Inhaled | “inhalation therapy” NCT00421122 ↗ |